Topics

FDA green lights next-gen sequencing platform for drug-resistant HIV

08:05 EST 10 Nov 2019 | MedCity News

STI, STD, testing, STI test, STD test, HIV, HIV test

The agency announced it had authorized Vela Diagnostics’ Sentosa SQ HIV Genotyping Assay, designed to help healthcare providers tailor antiviral therapy based on the presence of viral resistance mutations.

Original Article: FDA green lights next-gen sequencing platform for drug-resistant HIV

NEXT ARTICLE

More From BioPortfolio on "FDA green lights next-gen sequencing platform for drug-resistant HIV"

Quick Search

Relevant Topics

Assays
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...